Characteristics of 185 febrile, neutropenic patients treated for acute myeloid leukemia and by invasive aspergillosis.

Abbreviations: IA: invasive aspergillosis; IQR: interquartile range; HEPA: High-Efficiency Particulate Air.
aOf 11 IA, the independent blinded adjudication committee of the trial defined 2 proven IA and 9 probable IA according to international consensus definitions of 2002.
bBy chi-square test or exact Fisher test for binary variables; by Wilcoxon sum-rank test for continuous variables.
cProphylaxis included oral amphotericin B (n = 54), fluconazole (n = 23), and/or itraconazole (n = 10).
dOf 11 IA, 7 IA were documented by procedures before or within 24 h after the first dose of antifungal therapy, and 4 breakthrough IA occurred after antifungal therapy was started.
eCauses of death included 2 IA, 4 bacterial sepsis, 1 cardiogenic shock, and 1 coma of unknown origin. Follow-up was censored at 14 days after neutropenia recovery or at 60 days of neutropenia.